

Morphology and Morphogenesis of SARS-CoV-2 in Vero-E6 cells

Debora Ferreira Barreto Vieira (✉ df.barreto@globo.com)

Instituto Oswaldo Cruz, Fundação Oswaldo Cruz

Marcos Alexandre Nunes da Silva

Instituto Oswaldo Cruz, Fundação Oswaldo Cruz

Cristiana Couto Garcia

Instituto Oswaldo Cruz, Fundação Oswaldo Cruz

Milene Dias Miranda

Instituto Oswaldo Cruz, Fundação Oswaldo Cruz

Aline Rocha Matos

Instituto Oswaldo Cruz, Fundação Oswaldo Cruz

Braulia Caetano

Instituto Oswaldo Cruz, Fundação Oswaldo Cruz

Paola Cristina Resende

Instituto Oswaldo Cruz, Fundação Oswaldo Cruz

Fernando Mota

Instituto Oswaldo Cruz, Fundação Oswaldo Cruz

Marilda Mendonça Siqueira

Instituto Oswaldo Cruz, Fundação Oswaldo Cruz

Ortrud Monika Barth

Instituto Oswaldo Cruz, Fundação Oswaldo Cruz

Research Article

Keywords: SARS-CoV-2, Vero-E6 cells, morphology, morphogenesis

Posted Date: July 9th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-40432/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **Morphology and Morphogenesis of SARS-CoV-2 in Vero-E6 cells**

2 Debora Ferreira Barreto-Vieira¹, Marcos Alexandre Nunes da Silva¹, Cristiana Couto
3 Garcia², Milene Dias Miranda², Aline Rocha Matos², Braulia Caetano², Paola Cristina
4 Resende², Fernando Motta², Marilda Mendonça Siqueira², Ortrud Monika Barth¹

5 ¹Laboratório de Morfologia e Morfogênese Viral, ²Laboratório de Vírus Respiratórios e do
6 Sarampo, Oswaldo Cruz Institute, Oswaldo Cruz Foundation.

7 Corresponding author: Debora Ferreira Barreto-Vieira (barreto@ioc.fiocruz.br)

8 **Abstract**

9 The coronaviruses (CoVs) called the attention of the world for causing outbreaks of severe
10 acute respiratory syndrome (SARS-CoV), in Asia in 2002-03, and respiratory disease in the
11 Middle East (MERS-CoV), in 2012. In December 2019, yet again a new coronavirus (SARS-
12 CoV-2) first identified in Wuhan, China, was associated with a severe respiratory infection,
13 known today as COVID-19. This new virus is highly transmissible, and quickly spread
14 throughout China and 30 additional countries. As result, the World Health Organization
15 (WHO) elevated the status of the COVID-19 outbreak from emergency of international concern
16 to pandemic on March 11, 2020. The impact of COVID-19 on public health and economy
17 fueled a worldwide race to approve therapeutic and prophylactic agents, but so far, there are
18 no specific antiviral drugs or vaccines available. In current scenario, the development of *in*
19 *vitro* systems for viral mass production and for testing antiviral and vaccine candidates proves
20 to be an urgent matter. Research groups around the world are strongly focused on this, and the
21 susceptibility of different cell lines to SARS-CoV-2 infection has already been demonstrated
22 by molecular techniques. However, data on the biology of SARS-CoV-2 at the ultrastructural
23 level in these *in vitro* models is still scarce. In this study, we documented, by transmission
24 electron microscopy and real-time RT-PCR, the infection of Vero-E6 cells with SARS-CoV-2
25 samples isolated from Brazilian patients. The infected cells presented cytopathic effects and
26 SARS-CoV-2 particles were observed attached to the cell surface and inside cytoplasmic
27 vesicles. The entry of the virus into cells occurred through the endocytic pathway or by fusion
28 of the viral envelope with the cell membrane. Assembled nucleocapsids were verified inside
29 rough endoplasmic reticulum cisterns (RER). Viral maturation seemed to occur by budding of
30 viral particles from the RER into smooth membrane vesicles. Therefore, the susceptibility of
31 Vero-E6 cells to SARS-CoV-2 infection and the viral pathway inside the cells were
32 demonstrated by ultrastructural analysis.

33 **Key Words:** SARS-CoV-2, Vero-E6 cells, morphology, morphogenesis

34 **Introduction**

35 Coronavirus Disease 2019 (COVID-19) presents a clinical spectrum ranging from
36 asymptomatic individuals to more complex conditions such as severe acute respiratory
37 syndrome. Although most patients have mild symptoms and good prognosis, an estimate 10-
38 20% of individuals may be developed the severe forms of illness, and 2-5% may die due
39 complications in multiple organs. The pathogenesis of the disease related to the Severe Acute
40 Respiratory Syndrome of Coronavirus 2 (SARS-CoV-2) in humans is still unclear (Lin et al.,
41 2020). Among patients with pneumonia, fever was the most common symptom, followed by
42 cough (Sun et al. 2020). Bilateral pulmonary involvement was the most common finding from
43 chest computed tomography analysis (Lai et al., 2020). Dissemination of SARS-CoV-2 occurs
44 mainly by person-to-person transmission, through contact with respiratory fluids. It is
45 estimated that the infection has an average incubation period of six days.

46 COVID-19 was first identified in Wuhan, Hubei Province, Republic of China, on December
47 1st, 2019, but the initial reports only came out on December 31st of the same year. Since the
48 early stages of the epidemics, several evidences have pointed to a probable zoonotic origin for
49 SARS-CoV-2, in particular, the initial observation that first cluster of infections was linked to
50 a seafood and live animal wholesale market. Since its isolation from Wuhan samples in January
51 2020 (Lu et al., 2020), SARV-CoV-2 has quickly spread in China and many other countries
52 (Li et al., 2020; Gorbalenya et al., 2020; Chen et al., 2020; Huang et al., 2020; Wang et al.,
53 2020; Holshue et al., 2020). On January 30th 2020, the WHO declared COVID-19 as the sixth
54 public health emergency of international concern and, on March 11th 2020, raised the
55 classification of SARS-CoV-2 outbreak to pandemic. By the time of the WHO announcement,
56 more than 118,000 people had already been infected in 114 countries
57 ([https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10)
58 [covid-19.pdf?sfvrsn=1ba62e57_10](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10)).

59 SARS-CoV-2 is an enveloped, positive-sense RNA virus belonging to genus Betacoronavirus
60 (Chan et al., 2020; Lu et al.; 2020; Zhu el al., 2020). Phylogenetic analysis revealed that SARS-
61 CoV-2 is closely related (88-89% similarity) to SARS-like coronaviruses from bats, such as
62 bat-SL-CoVZC45 (GenBank no. MG772933.1) and bat-SL-CoVZXC21 (GenBank no.
63 MG772934.1), and shares lower similarity to SARS-CoV (~79% similarity) and MERS-CoV
64 (~50% similarity) [Lu et al, 2020; Jiang et al., 2020; Ren et al., 2020]. SARS-CoV-2 virions
65 (infectious particles) have a diameter of approximately 50 to 200nm. Like in other
66 coronaviruses, the SARS-CoV-2 lipid envelope contains a spike protein (S), a membrane

67 protein (M) and an envelope protein (E). The S protein mediates viral binding to the host cell
68 membrane through interaction with the angiotensin conversion enzyme (ACE2) receptor
69 (Hoffmann et al., 2020). The nucleocapsid protein (N) forms the virion core, which encases the
70 viral RNA genome (Chen et al., 2020; Wu et al., 2020). Currently there are no specific antiviral
71 drugs or vaccines for treating and preventing COVID-19. There are, though, several candidates
72 in different stages of development, with few recently reaching the phases of clinical testing.
73 Standardized in vitro systems for viral mass production and infection modeling are essential
74 tools to accelerate the initial steps of drug development, screening and pre-clinical testing. In
75 this sense, several research groups have demonstrated the susceptibility of different cell lines
76 to SARS-CoV-2 through molecular techniques (Park et al., 2020; Harcourt et al., 2020; Kim et
77 al., 2020). However, studies regarding the morphogenesis of SARS-CoV-2 in cell lineages are
78 scarce in the literature so far. Here, we used a lineage of African green monkey kidney cells
79 (Vero-E6) to isolate SARS-CoV-2 viruses from samples of nasopharyngeal swabs of patients
80 positive for COVID-19. Using transmission electron microscopy, we were able to document
81 the morphology and replication cycle of SARV-CoV-2, and the consequent ultrastructural
82 alterations induced in the host cells.

83

84 **Materials and Methods**

85 *Clinical samples*

86 Nasopharyngeal swabs were collected from patients admitted to the sentinel health units of the
87 national surveillance network for respiratory of the Brazilian MoH. Samples were obtained in
88 different regions of the country and referred to the National Influenza Center (NIC) at Fiocruz,
89 Rio de Janeiro for SARS-CoV-2 detection, as part of the COVID-19 surveillance program.
90 Total RNA was extracted from clinical samples using the QIAmp Viral RNA mini kit (Qiagen).
91 Viral detection was done by real time RT-PCR with TaqMan primers and probes (IDT) specific
92 for the genes encoding the Envelope protein (E) and the viral RNA-dependent RNA
93 Polymerase (RdRp), as described previously (Corman et al., 2020). Reactions were performed
94 with the Qiagen One Step RT-PCR kit (Qiagen, USA). Synthetic RNA sequences
95 corresponding to E and RdRP targets (Corman et al., 2020) were used as positive controls.
96 Positive samples were then used for SARS-CoV-2 isolation in VERO E6 cells. This research
97 is approved by Human Research Ethics Committee of Fundação Oswaldo Cruz, Instituto
98 Oswaldo Cruz (protocol number 4.128.241).

100 *Cells and viral isolation*

101 All cell culture reagents were acquired from Gibco. Prior to infection, Vero-E6 (African green
102 monkey kidney) cultures were maintained in DMEM supplemented with 10% fetal bovine
103 serum (FBS) and 100U/mL of penicillin-streptomycin (1x Pen-Strep) and cultured at 37° C and
104 5% CO₂ (Szretter, 2006). For infection, monolayers were washed twice with PBS and
105 inoculated with a clinical sample diluted in non-supplemented DMEM. Non-infected control
106 cultures (mock) were prepared using pure non-supplemented DMEM as inoculum. After
107 incubation for 1 hour at 37° C, the viral (and mock) inoculum was removed and cells were
108 cultivated at 37° C in DMEM supplemented with 2% FBS and 1x Pen-Strep. Monolayers were
109 inspected daily under light microscope for development of cytopathic effect (CPE), until 72
110 hours post infection (hpi). All procedures were performed in a biosafety level 3 laboratory,
111 according to WHO guidelines. Whole-genome sequences of isolates evaluated in this study are
112 available in the Global initiative on sharing all influenza data (GISAID) under the accession
113 numbers EPI_ISL_415105, EPI_ISL_414045 e EPI_ISL_427294 (<https://www.gisaid.org/>).

114

115 *Viral quantification in cell cultures supernatants*

116 Viral quantities in cultures were estimated by determination of the number of copies of the
117 viral gene E per volume (µL) of supernatant. Total RNA was extracted from culture
118 supernatants using the QIAmp Viral RNA mini kit (Qiagen). Quantification of E gene copies
119 was performed by real time RT-PCR using specific TaqMan primers and probes (Corman et
120 al., 2020) and the Qiagen one step RT-PCR kit (Qiagen, USA). A standard curve was set using
121 a synthetic RNA control containing the sequence of E gene. The control, with initial
122 concentration from 10⁸ copies/µL, was serially diluted (with factor 10) to obtain a series of 10⁷
123 copies/µL to 10 copies/µL.

124

125 *Transmission electron microscope*

126 Infected and non-infected control (Mock) monolayers were trypsinized at 24, 48 and 72 hpi.
127 Cell suspensions were fixed in 2.5% glutaraldehyde in sodium cacodilate buffer (0.2 M, pH
128 7.2), post-fixed in 1% buffered osmium tetroxide, dehydrated in acetone, embedded in epoxy
129 resin and polymerized at 60° C over the course of three days (Barreto-Vieira et al., 2010; Barth
130 et al., 2016). Ultrathin sections (50–70 nm) were obtained from the resin blocks. The sections
131 were picked up using copper grids, stained with uranyl acetate and lead citrate (Reynolds,

132 1963), and observed using Jeol JEM 1011 and FEI Tecnai T12 transmission electron
133 microscopes.

134

135 **Results**

136 *SARS-CoV-2 quantification from Vero-E6 cell culture supernatants*

137 To evaluate the ability of Vero-E6 cells to produce SARS-CoV-2 progeny, we quantified the
138 number of copies of viral RNA in culture supernatants collected one and 72 hours post infection
139 (hpi). The quantitative real time RT-PCR assay demonstrated an increase in the amount of
140 SARS-CoV-2 RNA copies in the supernatant over three log₁₀ steps within 72 hpi, from
141 $1,2 \times 10^4 (\pm 6,7 \times 10^4)$ to $1,4 \times 10^7 (\pm 1,6 \times 10^6)$ copies/mL, suggesting productive viral infection.

142


143 *Morphological analysis of Vero-E6 cell cultures infected with SARS-CoV-2*

144 Analysis of cultures under inverted light microscopy demonstrated CPE in infected Vero-E6,
145 which was mostly evident from 48 hpi. The CPE appeared as rounding and detaching of cells
146 and formation of syncytia (data not shown).

147 Ultrastructural analyses of Vero-E6 cells at 72 hpi by transmission electron microscopy showed
148 that the predominant changes associated to SARS-CoV-2 infection were, as follows: cell
149 activation evidencing strong filopodia presence (Figures 1B and 1C), alteration and
150 degeneration of mitochondria (Figures 2A-2D), an increased number of thickened ribosomes
151 (Figure 2E), thickening of the nuclear membrane (data not shown) and RER (Figure 2A-2B,
152 2F and 6D), presence of clathrin vesicles (Figure 2F), smooth vesicle proliferation resulting in
153 a severe vacuolization of the cells (Figures 3A-3D), numerous myelin figures (Figures 3E), and
154 chromatin profile change in the nucleus (Figures 4A-4C). As compared with the infected cells,
155 no ultrastructural changes were observed in the uninfected Vero cells (Figure 1A).

156 Virus particles attached to the cell surface (Figures 5A-5C and 5E) and envelopes fusing with
157 the cell membrane (Figure 5H) could be observed. Entry of the SARS-CoV-2 virus particles
158 into the cells was observed through fusion of the virus envelope with the cell membrane (Figure
159 5H) or by endocytosis (Figures 5D, 5F, 5G). Virus particles presented spherical morphology
160 displaying spikes on its surface (Figure 5G), characteristic of viruses belonging to the
161 *Coronaviridae* family and have an average diameter of 100nm. Nucleocapsids were observed
162 inside in the swollen RER (Figures 6A-6C). The thickened ribosomes attached to the RER
163 membrane were present at few numbers or disappeared completely (Figures 6A-6C).

164 Nucleocapsids were rarely observed associated with the nucleus membrane (Figure 4D). The
165 virions were observed inside smooth vesicles at the periphery of the cell (Figures 6D-6F).
166




177
178
179
180
181
182
183

184 **Figure 1.** Ultrastructural analyses of Vero-E6 cells by transmission electron microscopy. [A]:
185 Uninfected cell presenting no morphological alterations. [B-C]: Vero-E6 cells, 72hpi. with
186 SARS-CoV-2, presenting numerous filopodia (arrows) and vesicles (V). Nucleus (N), cell
187 cytoplasm (CC).

188

189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210



211 **Figure 2:** Ultrastructural alterations in Vero-E6 72hpi. with SARS-CoV-2. [A-D]: Alterations
212 and degeneration of mitochondria (*). [E]: Cell cytoplasm (CC) of electron-dense aspect due






213 to thickening of the ribosomes. [A, F]: Thickening of the rough endoplasmic reticulum cistern
214 (star). [F]: Presence of clathrate vesicles (arrow heads, inset). Nucleus (N), cell cytoplasm (CC).

215

216

217

218



243 **Figure 3:** Intense smooth vesicle proliferation (V) in Vero-E6 72hpi with SARS-CoV-2. [A-
244 D]: Vesicle (V) proliferation. Virus particle (B, arrow), nucleus (N). [E]: Cell cytoplasm
245 presenting numerous myelin figures (*).

246

247

248

249

250

251



252

253

254

255

256



259



260

261

262

263

264



265


266 **Figure 4:** [A-C]: Alterations of the nucleus (N) chromatin profile in Vero-E6 72hpi with
267 SARS-CoV-2. [D]: Viral nucleocapsid associated with the nucleus membrane (arrow). Cell
268 cytoplasm (CC).

269

271

272

273





275

276

277

278

279



280

281




282

283

284

285

286



287

288



289

290

291


292

293



294 **Figure 5:** Attachment and entry of SARS-CoV-2 in Vero-E6 cells 72hpi [A, B, C, E]: Several
295 virus particles (arrows) attached to cell membranes were observed. [D, F, G]: Entry of virus
296 particles into cells by the endocytic pathway and by fusion of virus envelopes with cell
297 membranes (head arrows) [G, H]: Virus particles presenting spherical morphology, displaying
298 spikes, and an average diameter of 100nm. Cell cytoplasm (CC).

299



318 **Figure 6:** Morphogenesis of SARS-CoV-2 in Vero-E6 cells 72hpi [A, B, C]: Nucleocapsids
319 inside swollen RER (circles). [D, E, F]: Virions were observed inside smooth vesicles at the
320 periphery of the cell (circles and arrow). [D]: Thickening of a rough endoplasmic reticulum
321 cistern (asterisk) including a dense electron matrix. Nucleus (N).

322


323

324

325 **Scheme of the Morphogenesis of the SARS-CoV-2**

326 Based on ultrastructural analyses of Vero-E6 cells infected with SAR-Cov-2, we propose a
327 scheme for the morphogenesis of the virus (Figure 7):

- 328 1. **Entry of the virus:** It may take place through the endocytic pathway (A) or by fusion
329 of the viral envelope with the cell membrane (B).
- 330 2. **Synthesis and assembly:** As only nucleocapsids were observed in cisterns of the RER
331 (C), we hypothesize that part of the assembly occurs in the RER. As a rare observation,
332 nucleocapsids were found attached to the cell nucleus (D), which suggests the
333 participation of the nucleus in viral synthesis. Virions were observed only inside smooth
334 vesicles (E) located in the peripheral part of the cell, suggesting that the nucleocapsids
335 acquire the envelopes by budding from the RER into these vesicles.
- 336 3. **Release of viral progeny:** Given the location of the vesicles containing the virions, it
337 is possible that the release of the viral progeny occurs throughout the fusion of the
338 smooth vesicles with the cell membrane (F).



352 **Figure 7:** Suggested steps of SARS-CoV-2 morphogenesis in Vero-E6 cell

353 Discussion

354 In the present study, using different parameters, we were able to show that Vero-E6 cells are
355 highly permissive to SARS-CoV-2 replication. We observed a logarithmic increase in the
356 number of viral RNA copies in cell culture supernatants, the display of a characteristic
357 cytopathic effect in cell monolayers, and profound alterations in cell ultrastructure, as well as
358 accumulation of viral components and viral particles in different cell compartments and times
359 after infection. These data corroborate those of Park et al. (2020) and Harcourt et al. (2020)
360 that described the susceptibility of this cell lineage for SARS-CoV-2 infection. These authors
361 suggest that Vero-E6 cells might be the best choice for amplification and quantification of the
362 virus. Transmission electron microscopy showed that the predominant changes associated to
363 SARS-CoV-2 infection were cell activation, alteration of mitochondria, thickening of the RER
364 and smooth vesicle proliferation, resulting in a severe vacuolization of the cells. Our findings
365 are corroborated by the studies carried out by Qinfen et al. (2004) with SARS-CoV, which also
366 observed that, as the infection progresses, the smooth vesicles increased both in number and
367 size. However, while these authors concluded that the smooth vesicles were derived from the
368 Golgi apparatus, our results suggest that they may be related to the RER.

369 To our knowledge, this is the first ultrastructural characterization of the morphogenesis of
370 SARS-CoV-2 during viral replication in a cellular model. Our analysis suggest that viral entry
371 into the host cell could occur either by endocytosis or by fusion of the viral envelope with the
372 cell membrane. This is consistent with information from literature, in which we could find
373 studies supporting both mechanisms (Song et al., 2019; Qinfen et al., 2004; Ng et al., 2003).
374 Nucleocapsids were observed inside RER cisterns, which presented thickening with a dense
375 electron matrix and gradual loss of ribosomes. This indicates that part of the SARS-CoV-2
376 protein synthesis and assembly may occur in the RER. Studies conducted by Zhang et al.
377 (2003a) and Qinfen et al. (2004) pointed that the core of SARS-CoV is initially assembled in
378 the RER, where the N protein binds to the genomic RNA and forms the nucleocapsid. The RER
379 gradually loses the ribosomes and swells to become the matrix vesicles that contain the viruses.
380 Qinfen et al. (2004) observed SARS-CoV-like particles in the nucleus of Vero-E6 cells at 48
381 hpi. Moreover, the nucleic membrane, being in connection with the RER, swelled to form blebs
382 that contained nucleocapsids. These blebs were seen to detach from the nucleic membrane and
383 turn into the virus morphogenesis matrix vesicles.

384

385 The presence of virions exclusively inside cytoplasmic smooth vesicles indicates that the
386 particles acquire their envelopes are delivered by budding from the RER directly into smooth
387 vesicles. This process is consistent with those observed with other coronaviruses. Qinfen et al.
388 (2004) demonstrated that the SARS-CoV viral nucleocapsids sprout during morphogenesis
389 from matrix vesicles into these smooth vesicles. In the last step of viral morphogenesis, we
390 observed the virion filled smooth vesicles accumulating in the periphery of the cytoplasm, close
391 to the cell membrane. Subsequent release of viral progeny occurred through the fusion of
392 smooth vesicles with the cell membrane. Similar release mechanisms were described for
393 SARS-CoV, which was also shown to accumulate inside smooth vesicles that move to the cell
394 periphery and eventually fuse with the cell membrane (Qinfen et al., 2004). The mature SARS-
395 CoV-2 virions had a spherical morphology, an average diameter of 100nm, and presented the
396 characteristic spikes on the envelopes, which is the signature morphological feature of the
397 coronaviruses. Again, our findings are very consistent with previous in vitro studies with
398 SARS-CoV (Qinfen et al., 2004) and SARS-CoV-2, although the last one was reported to
399 present some pleomorphism, and a wider range of virion diameter that varied from 50 to 200nm
400 (Zhu et al., 2020; Park et al., 2020; Chen et al., 2020; Wu et al., 2020).

401 Further immunomicroscopy and tomography studies are needed to get a better design of the
402 SARS-CoV-2 replication cycle, to better understand the role of the core of SARS-CoV-2
403 synthesis. The data presented in the present study are important for use in the development of
404 model systems to evaluate therapeutic approaches.

405

406 **ACKNOWLEDGEMENTS**

407 We thank Dra. Suzana Corte Real and Dr. Wendell Girard Dias (Rudolph Barth Microscopy
408 Platform, Oswaldo Cruz Institute, Fiocruz) and Jefferson Mendes de Miranda (SEJOR,
409 Oswaldo Cruz Institute, Fiocruz) for technical assistance, NB3 Platform (Oswaldo Cruz
410 Institute, Fiocruz) and CENABIO, Federal University of Rio de Janeiro, Brazil.

411

412 **References**

413 Barreto-Vieira, D.F., Barth-Schatzmayr, O.M. & Schatzmayr, H.G. (2010). Modelo animal
414 experimental para o estudo da patogênese dos vírus dengue sorotipos 1 e 2, manual de técnicas.
415 Interciência, Rio de Janeiro, 82. p.

416 Barth, O.M., da Silva M.A.N. & Barreto-Vieira, D.F. Low impact to fixed cell processing
417 aiming transmission electron microscopy. *Mem. Inst. Oswaldo Cruz*, **111(6)**:411–413 (2016).

418
419 Corman, V.M., et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.
420 *Euro Surveill.*, **25(3)**:1–8 (2020).

421

422 Chan, J.F., et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus
423 isolated from a patient with atypical pneumonia after visiting Wuhan. *Emerg. Microbes Infect.*,
424 **9**:221-236 (2020).

425 Chen, N., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel
426 coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*, **395**:507-513 (2020).

427

428 Gorbalenya, A.E. et al. Severe acute respiratory syndrome-related coronavirus: the species and
429 its viruses—a statement of the Coronavirus Study. Group bioRxiv (2020 Feb 11),
430 10.1101/2020.02.07.937862.

431 Harcourt, J. et al. Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with 2019
432 Novel Coronavirus Disease, United States. *Emerg. Infect. Dis.*, **26(6)** (2020).

433 Holshue, M.L., et al. First case of 2019 novel coronavirus in the United States. *N. Engl. J. Med.*
434 (2020 Jan 31), 10.1056/NEJMoa2001191.

435 Huang, C., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,
436 China. *Lancet*, **395**:497-506 (2020).

437

438 Jiang, S., Du, L. & Shi, Z. An emerging coronavirus causing pneumonia outbreak in Wuhan,
439 China: calling for developing therapeutic and prophylactic strategies. *Emerg. Microbes Infect.*,
440 **9**:275-277 (2020).

441

442 Kim, J.M., et al. Identification of Coronavirus Isolated from a Patient in Korea with COVID-
443 19. *Osong Public Health Res. Perspect.*, **11(1)**:3-7 (2020).

444

Lai, C.C., Tzu-Ping, S., Wen-ChienKo, H.J., & Po-RenHsueh. Severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The
epidemic and the challenges. *Int. J. Antimicrob. Ag.*, **55** (2020).

445

446 Li, Q., et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected
447 pneumonia. *N. Engl. J. Med.* (2020 Jan 29), 10.1056/NEJMoa2001316.

448

449 Lin, et al. 2020. Hypothesis for potential pathogenesis of SARS-CoV-2 infection -a review of
450 immune changes in patients with viral pneumonia. *Emerg Microbes Infect.*, **9(1)**:727-732
451 (2020)

452

453 Lu, H., Stratton, C.W. & Tang, Y.W. Outbreak of pneumonia of unknown etiology in Wuhan
454 China: the mystery and the miracle. *J. Med. Virol.* (2020 Jan 16), 10.1002/jmv.25678.

455

456 Lu, R., et al. Genomic characterization and epidemiology of 2019 novel coronavirus:
457 implications for virus origins and receptor binding. *Lancet*, **(20)**30251-8 (2020).

458

459 Ng, M.L., Tan, S.H., See, E.E., Ooi, E.E. & Ling, A.E. Early events of SARS coronavirus
460 infection in Vero cells. *J. Med. Virol.*, **71**: 323–331 (2003).

461

462 Park, W.B., et al. Virus Isolation from the First Patient with SARS-CoV-2 in Korea. *J. Korean*
463 *Med. Sci.*, **35(7)**:e84 (2020).

464

465 Qinfen, Z., et al. The life cycle of SARS coronavirus in Vero E6 cells. *J. Med. Virol.*,
466 **73(3)**:332-7 (2004).

467

468 Ren, L.L., et al. Identification of a novel coronavirus causing severe pneumonia in human: a
469 descriptive study. *Chin. Med. J. (Engl)*, **133(9)**:1015-1024 (2020).

470

471 Reynolds, E.S. The use of lead citrate at high pH as an electron-opaque stain in electron
472 microscopy. *J. Cell Biol.*,**17**:208-12 (1963).

473 Song, Z., et al. From SARS to MERS, Thrusting Coronaviruses into the Spotlight. *Viruses*,
474 **11(1)**: 59 (2019).

475

476 Sun, P., Qie, S., Liu, Z., Ren, J., Li, K., Xi, J. Clinical characteristics of 50 466 hospitalized
477 patients with 2019-nCoV infection. *J Med Virol* [Internet]. 2020 Mar 11;jmv.25735. Available
478 from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25735>

479

480 Szretter, K.J., Balish, A.L. & Katz, J.M. Influenza: propagation, quantification, and storage.
481 *Curr. Protoc. Microbiol.* Chapter 15, Unit 15G 1 (2006).

482

483 Wang, C. P.W., Horby, F.G. & Hayden, G.F. A novel coronavirus outbreak of global health
484 concern. *Lancet*, **395**:470-473 (2020).

485

486 Wu, C., et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs
487 by computational methods. *Acta Pharm. Sin. B.* 2020 Feb 27. doi: 10.1016/j.apsb.2020.02.008.

488

489 Zhang, Q., et al. Morphology and morphogenesis of severe acute respiratory syndrome
490 (SARS)- associated virus. *Acta Bioch. Bioph. Sin.*, **35**: 587–591(2003a).

491

492 Zhu, N., et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J*
493 *Med* (2020 Jan 24), 10.1056/NEJMoa2001017.

Figures




Figure 1

Ultrastructural analyses of Vero-E6 cells by transmission electron microscopy. [A]: Uninfected cell presenting no morphological alterations. [B-C]: Vero-E6 cells, 72hpi. with SARS-CoV-2, presenting numerous filopodia (arrows) and vesicles (V). Nucleus (N), cell cytoplasm (CC).




Figure 2

Ultrastructural alterations in Vero-E6 72hpi. with SARS-CoV-2. [A-D]: Alterations and degeneration of mitochondria (*). [E]: Cell cytoplasm (CC) of electron-dense aspect due to thickening of the ribosomes. [A, F]: Thickening of the rough endoplasmic reticulum cistern (star). [F]: Presence of clathrin vesicles (arrow heads, inset). Nucleus (N), cell cytoplasm (CC).




Figure 3

Intense smooth vesicle proliferation (V) in Vero-E6 72hpi with SARS-CoV-2. [A- D]: Vesicle (V) proliferation. Virus particle (B, arrow), nucleus (N). [E]: Cell cytoplasm presenting numerous myelin figures (*).




Figure 4

[A-C]: Alterations of the nucleus (N) chromatin profile in Vero-E6 72hpi with SARS-CoV-2. [D]: Viral nucleocapsid associated with the nucleus membrane (arrow). Cell cytoplasm (CC).




Figure 5

Attachment and entry of SARS-CoV-2 in Vero-E6 cells 72hpi [A, B, C, E]: Several virus particles (arrows) attached to cell membranes were observed. [D, F, G]: Entry of virus particles into cells by the endocytic pathway and by fusion of virus envelopes with cell membranes (head arrows) [G, H]: Virus particles presenting spherical morphology, displaying spikes, and an average diameter of 100nm. Cell cytoplasm (CC).




Figure 6

Morphogenesis of SARS-CoV-2 in Vero-E6 cells 72hpi [A, B, C]: Nucleocapsids inside swollen RER (circles). [D, E, F]: Virions were observed inside smooth vesicles at the periphery of the cell (circles and arrow). [D]: Thickening of a rough endoplasmic reticulum cistern (asterisk) including a dense electron matrix. Nucleus (N).




Figure 7

Suggested steps of SARS-CoV-2 morphogenesis in Vero-E6 cell